FG-3019  (Synonyms: Pamrevlumab; Anti-Human CTGF Recombinant Antibody)

FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF)^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

CTGF

FG-3019 (30 mg/kg; i.p. every 3 d for 9 d) in combination with Gemcitabine acutely decreases mouse pancreatic ductal adenocarcinoma (PDA) growth and induces neoplastic cell apoptosis in LSL-Kras^G12D/+;LSL-Trp53^R172H/+;Pdx-1-Cre (KPC) mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1490  [NCBI]

P29279

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.86 kDa

946415-13-0

Liquid

Colorless to light yellow

[FG-3019]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized CCN2/CTGF Protein, Human can bind Pamrevlumab . The EC₅₀ for this effect is 6.731 ng/mL.

• [1]. Sgalla G, et, al. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2020 Aug;29(8):771-777.  [Content Brief]

  [2]. Neesse A, et, al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30.  [Content Brief]